Search
Research
Coalition to Advance Vaccines Against Group A Streptococcus (CANVAS): A Trans-Tasman Initiative Against Rheumatic FeverInvestigators: Amy Baker, Jeffrey Cannon, Jonathan Carapetis, Katherine Gray, Yue Wu External collaborators: University of Auckland: Nikki Moreland,
Research
Developing a human challenge model of GAS infectionJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
END RHD Demonstration CommunitiesGlenn Jonathan Rosemary Pearson Carapetis AM Wyber BA (Education) PhD Candidate AM MBBS FRACP FAFPHM PhD FAHMS MBChB MPH FRACGP PhD Director of First
Research
Penicillin Levels for Rheumatic Heart Disease Study - WA Urban CohortJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Skin Care Assessment in Broome and Port Hedland (SCAB Heal) projectAsha Bowen BA MBBS DCH FRACP PhD GAICD FAHMS OAM Head, Healthy Skin and ARF Prevention Head, Healthy Skin and ARF Prevention Areas of expertise: Skin
The Strep A Translation team aim to understand the epidemiology of Strep A infections in Australia and the world. Alongside this, they explore the implementation of endgame recommendations, health economics and new horizons.
Research
Searching for a technology-driven acute rheumatic fever test: the START study protocolThe absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus.
Research
The economic and health burdens of diseases caused by group A Streptococcus in New ZealandIn preparation for the future arrival of a group A Streptococcus (GAS) vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand. The annual incidence of GAS diseases was based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-2016) and on the average number of hospitalizations occurring each year (2005-2014). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden.
Research
Increasing incidence of invasive group A streptococcal disease in Western Australia, particularly among Indigenous peopleThe incidence of invasive GAS disease in WA increased between 2000 and 2018, particularly among Indigenous Australians. Mandatory notification of invasive GAS disease would therefore be appropriate. The social determinants of differences in incidence should be addressed, and other relevant host, pathogen, and health system factors investigated.
Research
Structured review of primary interventions to reduce group A streptococcal infections, acute rheumatic fever and rheumatic heart diseaseRheumatic heart disease (RHD) is a large, preventable, global public health burden. In New Zealand (NZ), acute rheumatic fever (ARF) and RHD rates are highest for Māori and Pacific children. This structured review explores the evidence for primary prevention interventions to diagnose and effectively treat group A Streptococcus (GAS) pharyngitis and skin infections to reduce rates of ARF and RHD.